JPWO2021241523A1 - - Google Patents

Info

Publication number
JPWO2021241523A1
JPWO2021241523A1 JP2022526545A JP2022526545A JPWO2021241523A1 JP WO2021241523 A1 JPWO2021241523 A1 JP WO2021241523A1 JP 2022526545 A JP2022526545 A JP 2022526545A JP 2022526545 A JP2022526545 A JP 2022526545A JP WO2021241523 A1 JPWO2021241523 A1 JP WO2021241523A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526545A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021241523A1 publication Critical patent/JPWO2021241523A1/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022526545A 2020-05-25 2021-05-24 Pending JPWO2021241523A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020090526 2020-05-25
PCT/JP2021/019676 WO2021241523A1 (ja) 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Publications (1)

Publication Number Publication Date
JPWO2021241523A1 true JPWO2021241523A1 (ja) 2021-12-02

Family

ID=78744780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526545A Pending JPWO2021241523A1 (ja) 2020-05-25 2021-05-24

Country Status (7)

Country Link
US (1) US20230183347A1 (ja)
EP (1) EP4159235A1 (ja)
JP (1) JPWO2021241523A1 (ja)
KR (1) KR20230015348A (ja)
CN (1) CN115697405A (ja)
TW (1) TW202210099A (ja)
WO (1) WO2021241523A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4339289A1 (en) * 2021-05-13 2024-03-20 Foundation for Biomedical Research and Innovation at Kobe Anti-human pd-1 agonist antibody for treating or preventing inflammatory diseases, and pharmaceutical composition containing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2659270T3 (es) 2012-10-23 2018-03-14 Synaffix B.V. Anticuerpo modificado, conjugado de anticuerpo y proceso de preparación de los mismos
CN107149530A (zh) * 2016-03-04 2017-09-12 吴东 一种洗头装置
EP3515944A4 (en) * 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
CN106924718A (zh) * 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
TWI708787B (zh) * 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1促效劑抗體及其用途

Also Published As

Publication number Publication date
US20230183347A1 (en) 2023-06-15
TW202210099A (zh) 2022-03-16
KR20230015348A (ko) 2023-01-31
EP4159235A1 (en) 2023-04-05
WO2021241523A1 (ja) 2021-12-02
CN115697405A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
BR112023012656A2 (ja)
JPWO2022239820A1 (ja)
BR102021015500A2 (ja)
JPWO2021241523A1 (ja)
BR102021007058A2 (ja)
BR102020022030A2 (ja)
BR112023011738A2 (ja)
BR112023016292A2 (ja)
BR112023011539A2 (ja)
BR112023011610A2 (ja)
BR112023008976A2 (ja)
BR112023009656A2 (ja)
BR102021015450A8 (ja)
BR102021015247A2 (ja)
BR102021015220A2 (ja)
BR102021014056A2 (ja)
BR102021014044A2 (ja)
BR102021013929A2 (ja)
BR102021012571A2 (ja)
BR102021012230A2 (ja)
BR102021012107A2 (ja)
BR102021012003A2 (ja)
BR102021010467A2 (ja)
BR102021009555A2 (ja)
BR102021009475A2 (ja)

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318